Hortobagyi GN - Search Results

1

Supplement use during an intergroup clinical trial for breast cancer (S0221).

Zirpoli GR, Brennan PM, Hong CC, McCann SE, Ciupak G, Davis W, Unger JM, Budd GT, Hershman DL, Moore HC, Stewart J, Isaacs C, Hobday T, Salim M, Hortobagyi GN, Gralow JR, Albain KS, Ambrosone CB. Zirpoli GR, et al. Among authors: hortobagyi gn. Breast Cancer Res Treat. 2013 Feb;137(3):903-13. doi: 10.1007/s10549-012-2400-2. Epub 2013 Jan 10. Breast Cancer Res Treat. 2013. PMID: 23306462 Free PMC article.

2

Overview of new treatments for breast cancer.

Hortobagyi GN. Hortobagyi GN. Breast Cancer Res Treat. 1992;21(1):3-13. doi: 10.1007/BF01811959. Breast Cancer Res Treat. 1992. PMID: 1356516

3

Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer.

Macheledt JE, Buzdar AU, Hortobagyi GN, Frye DK, Gutterman JU, Holmes FA. Macheledt JE, et al. Among authors: hortobagyi gn. Breast Cancer Res Treat. 1991 Aug;18(3):165-70. doi: 10.1007/BF01990032. Breast Cancer Res Treat. 1991. PMID: 1756259 Clinical Trial.

4

Trilostane with hydrocortisone in treatment of metastatic breast cancer.

Chu PS, Buzdar AU, Hortobagyi GN. Chu PS, et al. Among authors: hortobagyi gn. Breast Cancer Res Treat. 1989 Mar;13(2):117-21. doi: 10.1007/BF01806523. Breast Cancer Res Treat. 1989. PMID: 2659103 Clinical Trial.

5

Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience.

Cristofanilli M, Holmes FA, Esparza L, Valero V, Buzdar AU, Neidhart JA, Hortobagyi GN. Cristofanilli M, et al. Among authors: hortobagyi gn. Breast Cancer Res Treat. 1999 Apr;54(3):225-33. doi: 10.1023/a:1006104610727. Breast Cancer Res Treat. 1999. PMID: 10445421 Clinical Trial.

6

Relapse after complete response to anthracycline-based combination chemotherapy in metastatic breast cancer.

Pusztai L, Asmar L, Smith TL, Hortobagyi GN. Pusztai L, et al. Among authors: hortobagyi gn. Breast Cancer Res Treat. 1999 May;55(1):1-8. doi: 10.1023/a:1006161906667. Breast Cancer Res Treat. 1999. PMID: 10472774

7

Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease.

Rivera E, Holmes FA, Buzdar AU, Asmar L, Kau SW, Fraschini G, Walters R, Theriault RL, Hortobagyi GN. Rivera E, et al. Among authors: hortobagyi gn. Breast J. 2002 Jan-Feb;8(1):2-9. doi: 10.1046/j.1524-4741.2002.08002.x. Breast J. 2002. PMID: 11856154 Clinical Trial.

8

The status of breast cancer management: challenges and opportunities.

Hortobagyi GN. Hortobagyi GN. Breast Cancer Res Treat. 2002 Oct;75 Suppl 1:S61-5; discussion S57-9. doi: 10.1023/a:1020326219576. Breast Cancer Res Treat. 2002. PMID: 12353825 Review.

9

Estrogen receptors and distinct patterns of breast cancer relapse.

Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN. Hess KR, et al. Among authors: hortobagyi gn. Breast Cancer Res Treat. 2003 Mar;78(1):105-18. doi: 10.1023/a:1022166517963. Breast Cancer Res Treat. 2003. PMID: 12611463

10

New approaches to breast cancer therapy.

Hortobagyi GN. Hortobagyi GN. Breast Cancer Res Treat. 2003;80 Suppl 1:S1-2; discussion S13-8. doi: 10.1023/a:1025447813637. Breast Cancer Res Treat. 2003. PMID: 14535529

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,102 results

Search Page